Notably, in this model, the introduction of antibodies against TGF-β1 resulted in increased proliferation of primary AML cells; however, this increase did not reach statistical significance in terms of the number of cells treated with cytarabine (Schelker et al., 2018). The gene discussed is TGFB1; the disease is acute myeloid leukemia.